Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Katowice – page 87

1 177 clinical trials in Katowice, Poland across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Katowice at a glance
1 177
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

1 177 trials in Katowice

Open in trial search

Neoplasm malignant+1

Not recruiting

Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of Gliclazide MR, Dapagliflozin, and Metformin for Patients with Type 2 Diabetes Not Well Controlled with Dapagliflozin

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Osteoarthritis

Not recruiting

Effects of Diclofenac Diethylamine Gel on Physical Activity and Quality of Life in Patients with Mild Knee Osteoarthritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Diethylamine
  • Sponsor:Haleon CH SARL

Renal cell carcinoma

Not recruiting

Study of Belzutifan and Palbociclib for Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Novartis Pharma AG

Study on Long-Term Safety and Efficacy of ARO-APOC3 for Adults with Mixed Dyslipidemia

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of EDP-938 for Adults with High-Risk Respiratory Syncytial Virus (RSV) Infection

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zelicapavir
  • Sponsor:Enanta Pharmaceuticals Inc.

Asthma

Not recruiting

Study on the Effects of ARO-RAGE (ADS-015) for Patients with Inflammatory Lung Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Katowice

What the registry says about research in the country

01 Respiratory Conditions

Research focusing on respiratory health conditions, including studies on RSV infections in older adults and treatments for chronic obstructive pulmonary disease. Current trials are evaluating new vaccines and investigating innovative therapies for chronic rhinosinusitis.

  • RSV Vaccine Studies
  • COPD Treatment Evaluation
  • Chronic Rhinosinusitis Management
02 Neurological Disorders

Innovative research into neurodegenerative conditions, with a particular focus on Parkinson's disease treatments. Studies are examining new therapeutic approaches and investigating targeted treatments for early-stage Parkinson's.

  • Early Parkinson's Disease Interventions
  • LRRK2-Driven Parkinson's Research
  • Generalized Myasthenia Gravis Treatment
03 Dermatological Conditions

Comprehensive studies on inflammatory skin conditions, including trials for moderate to severe plaque psoriasis, genital psoriasis, and atopic dermatitis. Research focuses on evaluating new biological treatments and innovative therapies.

  • Plaque Psoriasis Treatments
  • Atopic Dermatitis Management
  • Novel Therapeutic Approaches
04 Oncology and Hematology

Advanced research in cancer treatment, particularly focusing on blood cancers and prostate cancer. Studies include innovative approaches for treating diffuse large B-cell lymphoma and acute myeloid leukemia.

  • Lymphoma Therapies
  • Leukemia Treatments
  • Prostate Cancer Management
05 Autoimmune Conditions

Research investigating treatments for various autoimmune disorders, including Sjögren's Syndrome and chronic inflammatory demyelinating polyneuropathy. Studies focus on evaluating new therapeutic agents and their long-term effectiveness.

  • Sjögren's Disease Therapies
  • CIDP Treatment Approaches
  • Inflammatory Disease Management
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.